Macular Edema and Macular Degeneration Market Report 2025

This report covers market characteristics, size and growth, segmentation, regional and country breakdowns, competitive landscape, market shares, trends and strategies for this market. It traces the market’s historic and forecast market growth by geography.

The macular edema and macular degeneration market size has grown strongly in recent years. It will grow from $9.65 billion in 2024 to $10.43 billion in 2025 at a compound annual growth rate (CAGR) of 8.1%. The growth in the historic period can be attributed to aging population, prevalence of diabetes, awareness and early diagnosis, global initiatives in eye health, pharmaceutical innovations, patient advocacy and support.

The macular edema and macular degeneration market size is expected to see strong growth in the next few years. It will grow to $13.71 billion in 2029 at a compound annual growth rate (CAGR) of 7.1%. The growth in the forecast period can be attributed to personalized medicine approaches, rising awareness in emerging markets, focus on combination therapies, integration with teleophthalmology services, global aging demographics. Major trends in the forecast period include advancements in sustained-release drug delivery, integration of gene therapies, development of novel imaging technologies, personalized treatment approaches based on biomarkers, teleophthalmology for remote monitoring, advancements in artificial intelligence for diagnostics.

The increasing diabetes population is expected to drive the growth of the macular edema and macular degeneration market. Diabetes is a chronic condition characterized by elevated glucose (sugar) levels in the blood, which can damage the blood vessels in the eye, leading to macular edema and macular degeneration. For example, in June 2024, the National Health Service (NHS England), a UK-based publicly funded healthcare system, reported that in 2023, the number of individuals diagnosed with pre-diabetes in England rose to 3,615,330, an 18% increase from 3,065,825 in 2022. Additionally, cases among those under 40 saw a nearly 25% rise, growing from 173,166 in 2022 to 216,440 in 2023. Thus, the growing diabetes population is driving the expansion of the macular edema and macular degeneration market.

The increasing prevalence of eye disorders is also expected to contribute to the growth of the macular edema and macular degeneration market. Eye disorders encompass a diverse range of conditions affecting the visual system, leading to vision impairment or other symptoms. Conditions such as wet age-related macular degeneration (AMD) can result in abnormal blood vessel growth and leakage, directly contributing to fluid buildup in the macula. For instance, in September 2023, National Eye Health Week, a UK-based government website, reported that late-stage age-related macular degeneration (AMD), the primary cause of blindness in the UK, is projected to increase by 25% by 2032. Additionally, early-stage AMD (drusen) is expected to increase by 16%, cataracts by 25%, and glaucoma by 17% by 2032. This underscores the significance of the increasing prevalence of eye disorders in driving the growth of the macular edema and macular degeneration market.

Leading companies operating in the macular edema and macular degeneration market are directing their efforts towards developing innovative products, such as Vabysmo (faricimab-svoa), to enhance their market position. Vabysmo (faricimab-svoa) is a medication designed for the treatment of neovascular age-related macular degeneration (nAMD) and diabetic macular edema (DME). For example, in January 2022, Genentech Inc., a US-based biotechnology corporation, received approval from the Food and Drug Administration for Vabysmo (faricimab-svoa). As a bispecific antibody targeting vascular endothelial growth factor (VEGF) and angiopoietin 2 (Ang-2), it represents the first bispecific monoclonal antibody for both disorders. The approval of Vabysmo marked a significant milestone for Genentech and Roche, positioning it as a potential blockbuster medication for the treatment of nAMD and DME.

In July 2024, Merck & Co. Inc., a US-based pharmaceutical and biotechnology company, acquired Eyebiotech Limited (Eyebio) for an undisclosed amount. This acquisition aims to strengthen and diversify Merck's late-stage pipeline by incorporating Restoret, an innovative late-phase candidate for treating diabetic macular edema (DME) and neovascular age-related macular degeneration (NVAMD). The deal enhances Merck's portfolio with cutting-edge treatments rooted in novel biology and genetics, targeting unmet medical needs in retinal diseases. Eyebiotech Limited (Eyebio) is a US-based biotechnology company specializing in ophthalmology, developing therapies for sight-threatening eye diseases such as macular edema and macular degeneration.

Major companies operating in the macular edema and macular degeneration market report are F. Hoffmann La Roche Ltd., AbbVie Inc., Bayer AG, Novartis AG, GlaxoSmithKline PLC, Amgen Inc., Regeneron Pharmaceuticals Inc., Biogen Inc., Bausch Health Companies Inc., Clover Therapeutics Inc., Santen Pharmaceutical Co. Ltd., Samsung Bioepis Inc., PanOptica Inc., Regen X Bio Inc., Aerie Pharmaceutical Inc., Apellis Pharmaceuticals Inc., Kubota Pharmaceutical Holdings Co. Ltd., Alimera Sciences Inc., Kodiak Sciences Inc., Acucela Inc., Editas Medicine Inc., IVERIC bio Inc., Lineage Cell Therapeutics Inc., Allegro Ophthalmic Ltd., Ampio Pharmaceuticals Inc., Neurotech Pharmaceuticals Inc., Graybug Vision Inc., Clearside Biomedical Inc., Ocugen Inc., Opthea Limited.

North America was the largest region in the macular edema and macular degeneration market in 2024. The regions covered in the macular edema and macular degeneration market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in the macular edema and macular degeneration market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

The macular edema and macular degeneration market consists of revenues earned by entities by providing services such as ophthalmic care, ophthalmologic evaluation, imaging and diagnostics, laser therapy, photodynamic therapy, and rehabilitation and low vision services. The market value includes the value of related goods sold by the service provider or included within the service offering. The macular edema and macular degeneration market also includes sales of surgical interventions, low vision aids, dietary supplements, retinal implants, and subretinal injections. Values in this market are ‘factory gate’ values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

Macular edema and macular degeneration are distinct eye conditions that can impact vision. Macular edema involves swelling in the retina's part at the back of the eye, leading to blurry vision. On the other hand, macular degeneration is a condition affecting the macula, which is responsible for central vision in the retina at the back of the eye. Both conditions can be triggered by various factors, including diabetic retinopathy, retinal vein occlusion, inflammation, as well as age, genetics, smoking, high blood pressure, and obesity.

The primary types of treatment for macular edema and macular degeneration include drug therapy and laser treatment. Drug therapy entails the use of pharmaceutical drugs or medications to address, manage, or alleviate medical conditions, diseases, or symptoms related to these eye conditions. It finds applications in treating macular edema, diabetic macular edema (DME), cystoid macular edema (CME), macular degeneration, dry age-related macular degeneration, and wet age-related macular degeneration. These treatments are administered by hospitals, clinics, and other end-users.

The macular edema and macular degeneration market research report is one of a series of new reports that provides macular edema and macular degeneration market statistics, including macular edema and macular degeneration industry global market size, regional shares, competitors with macular edema and macular degeneration market share, detailed macular edema and macular degeneration market segments, market trends and opportunities, and any further data you may need to thrive in the macular edema and macular degeneration industry. This macular edema and macular degeneration market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

This product will be delivered within 3-5 business days.